Davis R M Inc. Buys 793 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Davis R M Inc. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 103,378 shares of the company’s stock after acquiring an additional 793 shares during the period. Davis R M Inc. owned approximately 0.13% of IDEXX Laboratories worth $52,229,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC grew its position in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after acquiring an additional 527,460 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of IDEXX Laboratories by 696.0% in the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after purchasing an additional 308,493 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of IDEXX Laboratories by 3,325.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock valued at $111,229,000 after purchasing an additional 213,731 shares during the last quarter. American Century Companies Inc. raised its position in IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after purchasing an additional 177,226 shares during the period. Finally, 1832 Asset Management L.P. lifted its stake in IDEXX Laboratories by 4,193.1% in the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock worth $62,601,000 after purchasing an additional 125,498 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $417.24 on Monday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a market capitalization of $34.17 billion, a P/E ratio of 40.24, a P/E/G ratio of 3.64 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $460.86 and a two-hundred day simple moving average of $480.63.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the previous year, the firm posted $2.53 earnings per share. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on IDXX shares. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.